Clinical trial

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Lung Cancer

NCT03501056

StatusWITHDRAWN

Study typeINTERVENTIONAL

Start date2018-03-27

PhasePHASE2

Study timeline

Study start (actual)2018-03-27Date precision: day

Registry last updated2020-10-19

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Advanced Lung Cancerunresolved

Interventions

Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Lung cancerBIOLOGICAL

CryotherapyPROCEDURE

Sponsors & collaborators

Fuda Cancer Hospital, Guangzhoulead sponsor

Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.collaborator

Mapped research locations

GuangzhouGuangdong, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03501056 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.